PacBio v. Oxford Nanopore

Baker Botts LLP advised Oxford Nanopore on the deal.

The Court of Appeals for the Federal Circuit issued a unanimous Precedential Opinion and Judgment affirming the jury’s March 2020 verdict in the PacBio v. Oxford Nanopore case, that invalidated a number of PacBio patents.

This has been a long running dispute in which Oxford Nanopore has repeatedly prevailed. In 2018, Oxford Nanopore was found by the ITC not to infringe other patents wrongly asserted against it by PacBio. That ruling was also affirmed by the Federal Circuit. Oxford Nanopore is pleased with this outcome, which it anticipates effectively ends a series of frivolous disputes perpetrated by PacBio.

Oxford Nanopore continues to innovate and bring high-performance, disruptive sequencing products to a global community of scientists. PacBio argued that Oxford’s DNA sequencing systems infringed one PacBio patent. That complaint was later combined with infringement suits involving three other patents. PacBio sought royalties and financial losses on sales from Oxford Nanopore.

Oxford is represented by Baker Botts partners Stephen Hash (Austin, Picture); Elizabeth Durham Flannery (Houston); Michael Hawes (Houston); and David Wille (Dallas); senior associates Puneet Kohli, and associates Samoneh (Sammy) Kadivar, David Varghese and Alex Piala (Austin).

 

Involved fees earner: Elizabeth Durham Flannery – Baker Botts LLP; Stephen Hash – Baker Botts LLP; Michael Hawes – Baker Botts LLP; Samoneh Kadivar – Baker Botts LLP; Puneet Kohli – Baker Botts LLP; Alex Piala – Baker Botts LLP; David Varghese – Baker Botts LLP; David Wille – Baker Botts LLP;

Law Firms: Baker Botts LLP;

Clients: Oxford Nanopore Technologies Limited;

Martina Bellini

Author: Martina Bellini